Published on 01 January 2018

A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

GlaxoSmithKline

Description

The purpose of this study is to assess the impact of belimumab on immune response to pneumococcal vaccine in subjects with Systemic Lupus Erythematosus (SLE).

Citations (0)

No citations found

It looks like this dataset has no citations.

Mentions (0)

No mentions found

It looks like this dataset has not been mentioned in any sources.

Metrics

Dataset Index

0.8

FAIR Score

31%

Citations

Mentions

Metrics Over Time

Publication Details

DOI

10.25934/00001145

Publisher

Vivli

Assigned Domain

Subfield

Rheumatology

Field

Medicine

Domain

Health Sciences

Confidence Score

65%

Source

Scholar Data Model

Keywords

Conditions: Systemic Lupus ErythematosusInterventions: Belimumab plus Early VaccinationInterventions: Belimumab plus Late Vaccination

Normalization Factors

13.46

CTw

1.00

MTw

1.00